Results from the first-in-human Ventricular Catheter Ablation Study (VCAS) evaluating Field Medical’s FieldForce™ Ablation System have been published in Circulation. The peer-reviewed article reports six-month outcomes demonstrating 82% freedom from VT/VF recurrence or ICD therapy and a 98% reduction in ventricular arrhythmia burden, marking an important clinical milestone in pulsed field ablation for ventricular tachycardia.
Read the full press release here.
CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/ -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForce™ Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).
Read the full press release here.
CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 /PRNewswire/ —Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium), taking place Oct. 10–11 in Philadelphia..
Read the full press release here.